Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs CDT Equity (CDT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biodexa Pharmaceuticals American Depositary Shs is the larger company by market cap ($1.2 million vs $32,432), about 35.6 times the size. On valuation, CDT Equity trades at a lower trailing P/E (0.0x vs 0.0x for Biodexa Pharmaceuticals American Depositary Shs).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | CDT |
|---|---|---|
| Share price | $0.5237 | $0.80 |
| Market cap | $1.15M | $32.43K |
| 1-day change | -7.11% | -4.31% |
| P/E ratio (TTM) | 0.01 | 0.00 |
| EPS (TTM) | $63.74 | $90,812.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.05 | $28,400.00 |
| 52-week low | $0.511 | $0.796 |
| Distance from 52-week high | -98.99% | -100.00% |
| Analyst consensus | none | — |
| Avg. price target upside | +1601.36% | — |
| Average volume | 3.72M | 188.27K |
| Shares outstanding | 2.20M | 40.54K |
| Employees | 11 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biodexa Pharmaceuticals American Depositary Shs is about 35.6 times larger than CDT Equity by market value ($1.15M vs $32.43K).
- Biodexa Pharmaceuticals American Depositary Shs trades at a higher earnings multiple (0.0x vs 0.0x trailing P/E).
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About CDT Equity
CDT stock →CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
BDRX vs CDT FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or CDT Equity?
Biodexa Pharmaceuticals American Depositary Shs (BDRX) is larger, with a market capitalization of $1.15M compared with $32.43K for CDT Equity (CDT).
Which has the lower P/E ratio, BDRX or CDT?
CDT has the lower trailing P/E at 0.0, versus 0.0 for BDRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Biodexa Pharmaceuticals American Depositary Shs and CDT Equity in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.